RealTime Dynamix™: Hyperkalemia, June 2016
The sixth monthly update on the launch of Veltassa and the evolution of the Hyperkalemia market provided by 101 Nephrologists. Download Report Overview About Spherix Global Insights Spherix Global Insights is a newly established business intelligence and market research company headquartered in Cambridge, MA with EU offices in Zug, Switzerland. We specialize in renal, autoimmune, […]
RealTime Dynamix™: Renal Anemia, June 2016
Monthly report covering the dialysis and chronic kidney disease market for ESAs and IV Iron. Additional insight on the development pipeline including receptivity to biosimilar ESAs and growing awareness of a novel class of anemia agents, the HIF-PH inhibitors. n=104 nephrologists Download Report Overview About Spherix Global Insights Spherix Global Insights is a newly established […]
RealTime Dynamix™: Bone and Mineral Metabolism, June 2016
Monthly refresh for the US phosphate binder and secondary hyperparathyroidism market wth launch metrics for Auryxia and Velphoro with pre-launch insight on Parsabiv, Amgen’s IV calcimimetic. n=104 nephrologists Download Report Overview About Spherix Global Insights Spherix Global Insights is a newly established business intelligence and market research company headquartered in Cambridge, MA with EU offices […]
Relypsa’s Veltassa Continues An Upward Trajectory Among Nephrologists But Familiarity And Use Is More Muted Among Cardiologists
Download Report Overview The hyperkalemia market is poised for a massive paradigm shift as clinicians begin to embrace the concept of chronic treatment, according to several reports by Spherix Global Insights, GmbH ZUG, Switzerland, May 18, 2016 /PRNewswire/ — According to the most recent monthly nephrology survey fielded at the end of April (n=112), the […]
2016 Nephrology Publications
Our focus will be on bone and mineral metabolism, renal anemia, hyperkalemia, diabetic nephropathy, chronic kidney disease and dialysis. Monthly survey of highly dynamic markets, tracking brand usage, awareness, industry contacts and evolving perceptions. RealTime Dynamix: Bone and Mineral US 2016 RealTime Dynamix: Renal Anemia US 2016 RealTime Dynamix: Hyperkalemia US 2016 […]
Relypsa’s Veltassa Does Not Disappoint as Trial Increases Among US Nephrologists
Download Report Overview At three months post-launch, close to half of US nephrologists have prescribed Veltassa and the vast majority intend to increase their use in the near term, according to Spherix Global Insights, GmbH April 11, 2016 – Zug, Switzerland A recent survey conducted by Spherix Global Insights with 102 US nephrologists in late […]
Relypsa’s Launch of Veltassa™ Off to a Strong Start According to US Nephrologists
Download Report Overview At one month post-launch, one in five surveyed nephrologists has started to use Veltassa in clinical practice, according to Spherix Global Insights, GmbH February 11, 2016 – Zug, Switzerland A recent survey conducted by Spherix Global Insights with 101 US nephrologists in late January 2016, shows promising activity for Veltassa, the first […]
After a Lackluster Launch, Keryx’s Auryxia Appears to Be Moving in the Right Direction According to Spherix Global Insights Gmbh
Download Oct 14, 2015 – Zug, Switzerland – Feedback gathered from 300 US nephrologists in the last three releases of RealTime Dynamix: Bone and Mineral Metabolism, suggests that Auryxia is finally on the upswing. Despite strong buy-in to the benefits of Auryxia and a patient population that is largely above the target range for phosphorus, […]
Nephrologists Perceive the Anemia Effects of Keryx’s Auryxia to be Favorable, but Market Penetration at Six Months Post Launch is Low
Download Familiarity with Auryxia is the primary barrier to adoption and growth, according to Spherix Global Insights, GmbH August 20, 2015 – Zug, Switzerland –RealTime Dynamix: Nephrology reveals that while Keryx contact rates for Auryxia are in line with those of competitors, familiarity with the product remains low. Market access also appears to be a […]
